We report a 12% incidence of adenovirus infections among 532 recipients of hematopoietic stem cell transplant (HSCT) from January 1986 through March 1997. The median time from day of stem cell infusion to first positive culture was 41 days. Recipients of allogeneic stem cells, as opposed to autologous stem cell recipients, were more likely to have a culture positive for adenovirus (16% vs. 3%;
isolation of adenovirus from 4768 stem cell transplant recipients treated from 1976 to 1994 [11] . An improved understanding of the incidence and outcomes of adenovirus infections in HSCT recipients can serve as a basis for developing strategies for more effective treatment. We investigated adenovirus infections in our transplant population over a 10-year period. We report on the frequency and impact of adenovirus infections, as well as the incidence of and risk factors for invasive infection and prognosis in this patient population.
Patients and Methods
From 1 January 1986 through 31 March 1997, 532 patients underwent HSCT at our institution (the Lucille Parker Markey Cancer Center, Lexington, KY). A retrospective chart analysis identified 64 patients from whom a culture positive for adenovirus had been obtained during the pretransplant evaluation or at any time after transplantation. We reviewed the charts of these 64 patients for the following data: patient demographics, type of transplant and source of stem cells, conditioning regimen, T lymphocyte depletion of the stem cell product, graft-versus-host disease (GVHD) prophylaxis, presence of GVHD, therapies used to treat GVHD, time to engraftment, infections after transplantation, administration of iv immune globulin and/or acyclovir, day from stem cell infusion to first culture positive for adenovirus, number and specific sites of infection with adenovirus, presence of symptoms suggestive of a clinical syndrome associated with adenovirus, biopsy or autopsy confirmation of invasive infection, treatment rendered for positive adenovirus infection, and patient survival and cause of death (tables [1] [2] [3] .
Treatment regimens. Patients undergoing allogeneic transplantation from a partially matched or matched unrelated donor for hematologic malignancies were conditioned with a multidrug regDownloaded from https://academic.oup.com/cid/article-abstract/29/6/1494/307033 by guest on 02 March 2019 10 (16) imen that included cyclophosphamide, cytarabine either with or without etoposide or with or without busulfan, methylprednisolone, and fractionated total body irradiation at 14 Gy. Patients with a histocompatible sibling donor were treated with cyclophosphamide and busulfan or etoposide and total body irradiation at 14 Gy. Patients receiving transplants for hereditary metabolic disorders were treated with the same multidrug and total body irradiation regimen as patients with leukemia. Autologous transplant patients received disease-specific high-dose chemotherapy regimens. The stem cell products of HLA-matched related donors were not T lymphocyte-depleted. However, two-thirds of the 60 allogeneic transplant patients with cultures positive for adenovirus who received stem cells from HLA-matched unrelated donors or partially matched related donors did receive prophylaxis for GVHD, which included or consisted solely of T lymphocyte depletion of the stem cell product with the ab T cell receptor antibody T 10 B 9 [12] . Other routine GVHD prophylaxis was in vivo administration of CD5 monoclonal antibody (Xomazyme; XOMA, Berkeley, CA) or, in the later years of the survey period, a combination of cyclosporin A at 3 mg/kg/day and methylprednisolone at 30 mg/m 2 . Allogeneic transplant recipients who developed acute GVHD were initially treated with methylprednisolone at у2 mg/kg/day. Refractory cases of GVHD were treated with higher doses of steroids, antithymocyte globulin, and therapy with T lymphocyte-specific monoclonal antibodies. All patients received weekly iv immune globulin therapy for the first 100 days after transplantation.
Laboratory evaluation. Weekly surveillance cultures for virus were done from blood, saliva, and urine from all inpatients. Samples were also obtained and cultured as clinically indicated. The stem cell products for all patients were sent for routine culture of virus on the day of infusion. Outpatients had cultures done less routinely; surveillance samples for culture were often sent every 2-4 weeks throughout the first 100 days after transplantation. For outpatients, many samples were obtained and cultured on the basis of clinical symptoms. Biopsy and autopsy specimens were routinely sent for culture to the clinical virology laboratory at the University of Kentucky. Specimens were inoculated onto a human epithelial cell line, A-549 cells, for shell vial cultures, or, for standard tube cultures, onto primary rhesus monkey kidney cells, MRC-5 cells, and fibroblasts [13] [14] [15] . Cultures were observed for characteristic cytopathic effect for 21 days. Most cultures with cytopathic effect suggestive of adenovirus were confirmed immunohistologically with monoclonal antibody from Bartels (Issaquah, WA). No isolates were serotyped. Biopsy and autopsy specimens were processed for routine histological studies to detect viral pathogens; adenovirus was identified by characteristic histological changes.
Definitions. Patients were classified as having a positive culture if adenovirus was cultured у1 times from their body secretions or tissues, with or without the presence of characteristic histological changes of adenovirus on specimens obtained by biopsy or autopsy. Patients were considered to have noninvasive infections if their cultures revealed adenovirus but who did not manifest any clinical symptoms associated with adenovirus. Patients were considered to have invasive infections if a culture was positive or if showed a confirmatory histopathology manifesting typical symptoms of a clinical syndrome associated with adenovirus. If the only site from which a positive culture was obtained was the gastrointestinal tract, diagnosis of invasive infection required that a confirmatory histopathology be observed in addition to positive cultures and clinical symptoms. Typical symptoms of a clinically significant adenovirus infection for each site are defined as follows: for the gastrointestinal tract, diarrhea, grossly or microscopically positive for blood; for the urinary tract, hemorrhagic cystitis that may or may not be associated with renal failure; for the lungs, infiltrates on chest radiograph with or without cough and decreased oxygen saturation; for the brain and liver, no symptoms are considered suggestive (all invasive brain or liver infections were biopsy and/or autopsy proven) [7] . If cultures were negative from other symptomatic sites, positive cultures from nasopharynx, blood, or bone marrow bag were regarded as indicating asymptomatic infection.
Statistical analysis. Statistical analyses include comparisons done by use of the x 2 , Fisher's exact, or log rank tests. P р .05 was considered significant. A multivariate analysis was done by logistic regression to evaluate correlations among individual factors considered to potentially increase risk for invasive disease. Factors reviewed included stem cell donor source, age of the patient, presence of total body irradiation in the conditioning regimen, T lymphocyte depletion of the stem cell product, administration of antithymocyte globulin for acute GVHD therapy, number of sites of infection, presence of acute GVHD, and presence of coinfection with cytomegalovirus. Survival curves were generated by the Kap- lan-Meier method, and their equality was compared by the Wilcoxon and Ϫ2 log methods.
Results
During the study period of slightly more than 10 years, HSCTs were performed for 532 patients. From 64 (12%) of these, we obtained у1 cultures positive for adenovirus from у1 sites. The time between HSCT and first culture positive for adenovirus ranged from 9 months before to nearly 3 years after transplantation. However, the median time to first positive culture was 41 days from stem cell infusion; for 53 patients (83% ), this first positive culture was obtained within the first 100 days after transplantation. Our review did not reveal a seasonal pattern to infections, but there were trends toward clustering.
Two factors significantly altered the incidence of culture positivity: the age of the recipient and the type of HSCT. Pediatric patients were significantly more likely to have a positive culture: 29 (22.8%) of 127 pediatric patients, but only 35 (8.6%) of 405 adult transplant recipients ( ). Positive cultures were P ! .0001 also found predominantly among allogeneic transplant recipients: over a decade, 15.8% of patients in the allogeneic transplant population but only 2.7% of patients receiving autologous transplants (
; figure 1 ). There was no significant dif-P ! .0001 ference in the incidence of adenovirus infections among the different types of allogeneic transplants.
Over the span of this review, there was a significant change in the type of patients receiving stem cell transplants. During the first half of the study, nearly half of the patients were children, and the source of stem cells was predominantly allogeneic donors. In the latter half of the study, significantly fewer pediatric patients received transplants, and a greater proportion of transplantations were done with use of autologous stem cell support (figure 2). Despite this, there was no significant difference in the incidence of positive cultures from patients during the 2 halves of the study (13.7% in the first half vs. 9.6% in the latter half;
). P = .176 Forty-one of 64 patients with a culture positive for adenovirus had evidence of invasive disease. A multiple logistic regression analysis indicated that the most significant risk factor correlating with the development of invasive disease was the isolation of adenovirus from у2 sites ( ). Treatment for P = .002 adenovirus infection (iv immune globulin and/or ribavirin) was also significantly associated with invasive disease ( ) P = .02 -but only because the majority of patients who received such treatment were supected to have an invasive infection. Asymptomatic patients rarely received therapy. Despite the higher risk for pediatric patients to have a positive culture, the incidence of an invasive infection among children was no higher than that for adults.
In our cohort of 64 patients, 62.5% (40) had 11 positive culture and 39% (25) Forty-eight of 60 allogeneic stem cell transplant recipients developed GVHD. Forty-seven of those patients were treated with bolus dose steroids as minimal therapy (a у2 mg/kg dose of methylprednisolone followed by an extended taper); 1 patient with acute GVHD was given CD5 monoclonal antibody as primary therapy. GVHD was present in 81% of patients designated as having invasive disease (33 of 41), in contrast to 65% of patients with noninvasive infection (15 of 23; ). P = .38 Seven patients were treated with antithymocyte globulin for acute GVHD; treatment with antithymocyte globulin was not significantly correlated with invasive disease.
Among patients with invasive disease, adenovirus was most commonly isolated from the urinary tract (culture of urine; bladder or kidney biopsy or autopsy), gastrointestinal tract (culture of saliva or stool; endoscopic biopsy or autopsy), and lung (culture of sputum or bronchioalveolar lavage fluid; lung biopsy or autopsy). Among patients who were asymptomatic, culture samples were obtained especially from the urinary tract (urine) and the gastrointestinal tract (stool; table 6). Often, there were overlaps in the clinical manifestations of adenovirus infections and other conditions, such as acute GVHD or other infectious diseases. This was particularly evident in patients from whom adenovirus was isolated from the gastrointestinal tract and who had bloody diarrhea. For 6 of 41 patients with invasive disease, the single site from which adenovirus was isolated was the gastrointestinal tract; all of these patients had histopathology of biopsy specimens consistent with adenovirus infection; for 16 patients, adenovirus was isolated only from urine; hemorrhagic cystitis was present in 9 of these patients. Another 20 patients had adenovirus in their urine as well as у1 other sites; 18 of those patients had hemorrhagic cystitis. In 14 patients, adenovirus was recovered from lung tissue, bronchoalveolar lavage specimen, tracheal aspirate, or sputum. Of those patients, 10 died with progressive pneumonia and adult respiratory distress syndrome. Specimens recovered from liver, brain, blood, and nasopharynx were consistently associated with positive cultures from 11 site. Three patients had adenovirus recovered from culture of their stem cell product done on the day of stem cell infusion. Of those 3 patients, 1 developed fulminant and fatal adenovirus hepatitis and 2 remained asymptomatic without any further evidence of adenovirus infection. To our knowledge, this is the only report of cultures of the stem cell infusion product that were positive for adenovirus.
The median survival from day of stem cell infusion (day 0) for all patients with a culture positive for adenovirus was 208 days (7 months). Patients with evidence of invasive infection had a median survival of 100 days (3 months), whereas patients with noninvasive adenovirus infection had a median survival of 998 days (33 months). Of the 64 patients analyzed, 43.5% of asymptomatic patients survived versus 24.4% of patients with invasive disease (
[Wilcoxon]; [Ϫ2 log]; figure P = .05 P = .002 3). Of our cohort, 20 patients are still surviving. Of patient deaths, 25% (11 of 44) could be directly attributed to invasive adenovirus infection; 59% of deaths (26 of 44) were attributed to overwhelming infection due to у1 pathogens. Other causes of death included recurrence of the underlying disease (5), GVHD (5), and miscellaneous (8)-lymphoproliferative disease, pulmonary embolus, gastrointestinal hemorrhage, and unknown.
Autopsies were performed on 18 of the 44 patients who died. Nine (50%) of these yielded tissue cultures and/or histopathology that confirmed the presence of adenovirus. The other 9 autopsies failed to show histopathologic confirmation of invasive disease at the time of death. In 6 patients who died of multiple organ failure, adenovirus had been recovered from only a single site prior to death: stool (3 patients), urine (2), and blood (1). Autopsies for each of these 6 patients revealed multiple sites of invasive adenovirus. Autopsies of 3 other patients from whom adenovirus had been isolated from multiple urine cultures revealed hemorrhagic cystitis and histopathologic confirmation of invasive urinary tract infections. Forty-two of the patients with adenovirus were treated with supportive care only. Therapy beyond supportive care was initiated for patients believed at the time to have an invasive infection. Thirteen patients were treated with aerosolized and/ or iv ribavirin. Three of those patients and 9 others were given iv immune globulin for their adenovirus infection. One T lymphocyte-depleted, partially matched related stem cell recipient, who did not have GVHD but had aggressive hemorrhagic cystitis, nephritis, and obstructive renal failure believed secondary to adenovirus, was treated with donor leukocyte infusions after failing to respond to iv ribavirin, without eradicating the infection. A matched unrelated donor recipient being treated with steroids for acute GVHD received iv cidofovir after failing to clear adenovirus from the gastrointestinal and urinary tracts after 14 days of iv ribavirin and every-other-day iv immune globulin. No improvement was seen, and the patient died with progressive disseminated adenovirus infection.
There were some successes in eradicating adenovirus among patients treated with iv ribavirin. One patient manifested symptoms of viral upper respiratory tract infection, diarrhea, and a failure to thrive syndrome, and the only pathogen recovered was adenovirus from the stool. We initiated ribavirin therapy early, and all these symptoms cleared. Another patient, who had received a matched sibling donor transplant and was receiving steroids for acute GVHD, had adenovirus cultured from 3 sputum samples and a blood buffy coat sample. Intravenous ribavirin was initiated early, and adenovirus was cleared from all cultures after 7 days of therapy. Two patients with acute hemorrhagic cystitis who had adenovirus cultured from urine samples were treated early in their course with iv ribavirin and cleared all symptoms. One of those patients was an adult autologous transplant patient and the other a pediatric patient who had recevied partially matched related donor stem cells and no immunosuppression therapy. There was a trend toward better responses to ribavirin therapy among patients with a single site of infection if they were treated soon after isolation of the virus.
Discussion
The incidence of adenovirus reported among recipients of HSCT varies from 4.9% to 20.9% [1, [7] [8] [9] [10] [11] ; the 12% incidence in our transplant population is consistent with this. As in other published studies, this value is probably an underestimate, because the calculation of incidence is influenced by policies regarding the timing and indications for obtaining cultures, as well as the culture techniques used. Also, reviews such as ours depend on data generated from routine surveillance cultures, and must choose standard constellations of symptoms to indicate when samples should be obtained for culture. However, at best, collection of routine surveillance cultures is inconsistent. Nor is its necessarily clear which symptom complexes are most indicative of viral versus other infectious pathology. Moreover, economic constraints have caused our institution and others to discontinue routine surveillance cultures, and have steered us toward an aggressive symptom-directed culturing strategy. Thus detecting adenovirus infections often depends on high indexes of suspicion and low thresholds for obtaining samples for culture of virus. Is it unlikely that an invasive infection would go undetected; however, without routine surveillance cultures, culture-positive asymptomatic patients can and undoubtedly do remain undetected. The incidence of adenovirus reported here does not account for patients for whom viral illness is strongly suspected but from whom a pathologic organism is not recovered. Some serotypes of adenovirus are clearly more difficult to grow in cell cultures than are others [13] . If we are to make advances in the management of adenovirus infections, consistent and early detection of the organism is imperative.
We are among several investigators who have noted a higher incidence of adenovirus isolated from pediatric than from adult populations [1, 9] . The incidence of isolation of adenovirus was 22.8% in our pediatric subset of patients and 8.6% among adults ( ). In a Milwaukee transplant population, an overall P! .0001 incidence of 20.9% was reported [9] . Similar to our experience, the Milwaukee patients represented a mixture of adult and pediatric patients who were receiving predominantly allogeneic stem cell transplants and were treated with similar conditioning regimens, T lymphocyte depletion strategies, and acute GVHD therapies. However, in that study there were proportionately , Wilcoxon rank sum test). Median survival P = .05 was 998 days for asymptomatic patients with a positive isolate and 100 days for patients with invasive disease. more pediatric transplants than at our institution. The higher overall incidence of adenovirus they reported is consistent with the proportionately higher number of pediatric transplants.
The higher incidence of adenovirus isolates in pediatric patients is not entirely explained by a higher proportion of allogeneic stem cell recipients among children. In our study, pediatric recipients of an allogeneic transplant had a 24% incidence of isolation of virus, whereas 11.9% of adult allogeneic recipients had virus isolated ( ). In our patient P = .004 population there were proportionately more partially matched related donor transplantations done in pediatric patients. These transplants are generally associated with more immunosuppression and risk of infectious complications. We completed 75 partially matched related donor pediatric transplants (62% of allogeneic transplants in children) and 79 such adult transplants (30% of allogeneic transplants in adults). Regardless of age, nearly all of the partially matched related donor patients had GVHD prophylaxis that included T lymphocyte depletion. We obtained adenovirus isolates from 23 (31%) of the pediatric partially matched related donor patients and 7 (9%) of the adult partially matched related donor patients ( ). We found P ! .001 a disproportionate representation of adenovirus infections among children, which cannot be ascribed to the type of transplant they received.
During the second half of our study, there was a significant change in the type of transplants completed at the University of Kentucky (figure 2). It is particularly intriguing that despite a significant decrease in transplants performed for patients thought to have an increased risk of adenovirus (pediatric and allogeneic), the overall incidence of adenovirus isolation was not statistically significantly lower than in the first half of the study. We saw no decrease in overall incidence of adenovirus infection paralleling the decrease in numbers of transplants of the types associated with increased susceptibility to adenovirus; this implies an increasing rate of infection in susceptible patients. In fact, the incidence of adenovirus infection in all patients increased over time in our study, although not significantly in any subset. Bruno et al. [11] divided the incidence of adenovirus infections in Seattle's transplant population into 6 periods of 3 years. While maintaining a rather homogeneous transplant population, they reported an increase in incidence, from 3.5% during 1976-1978 to 12.4% during 1991-1993. It is not clear why the incidence of adenovirus infections would be increasing in the transplant population. Some of the increase in incidence may be attributed to more aggressive viral culturing practices and/or to better methods for detecting adenovirus in laboratory culture. In some institutions, an increasing incidence might be related to increases in the numbers of higher-risk transplants and more intensive immunosuppression.
It is widely recognized that not all patients who have adenovirus isolated from culture develop symptoms attributable to adenovirus infection [7] [8] [9] [10] [11] . Furthermore, not all patients who develop symptoms of a clinical syndrome associated with adenovirus will have the same clinical course. Although some patients manage to eradicate their infection, others die of disseminated infection with multiorgan failure. It is possible that part of understanding the variable clinical course of adenovirus infection lies in understanding more about the source of the infection or previous exposure to the virus. Since most people are first exposed to adenovirus in childhood, there may be an increased susceptibility among previously unexposed children. It is not likely that all infections in HSCT recipients are cases of primary infection, since we know that the majority of schoolage children will have antibodies to у1 serotypes of adenovirus [2, 16] . It is also possible that some patients are being exposed to a new serotype. This explanation seems less likely, given the overlap in some adenovirus serotypes reported among transplant patients and those causing community infections in normal hosts [13, 17] . Finally, studies of antibody status indicate that many patients were seropositive for adenovirus before transplantation. One study used complement fixation to test for antibody to adenovirus in pretransplantation serum samples from patients and their donors, and found that 33 of 48 patients were seropositive, a finding consistent with prior exposure to adenovirus. It is possible that adenovirus infections could represent reactivation of endogenous latent infection [10, 17] . Certainly, adenoviruses induce latent infections in tonsils, adenoids, and other lymphoid tissues [16] [17] [18] . In the above review [8] , 30 of the 45 donors were positive, which raises the possibility that adenovirus infection can be transmitted from donor organ to recipient. This should perhaps be a compelling concern, since that we have documented at least 1 case in which a stem cell product positive for adenovirus was given to a patient who subsequently died of fulminant hepatitis due to adenovirus. At this time, it is not clear whether there exists a single model for pathogenesis of adenovirus infection in transplant patients.
Previous authors have defined the criteria for invasive infection differently [9] [10] [11] . In our review, we recognize 2 groups of infected patients: culture-positive patients who are asymptomatic, and culture-positive patients who have symptoms attributable to adenovirus and/or histopathologic evidence of disease. The majority of our patients fall into the latter group. It is important to note that even though pediatric patients have a higher incidence of adenovirus isolation, their risk of contracting an invasive infection is no different than it is for adult patients. One factor correlates highly significantly with the propensity to have what we defined as invasive disease: the isolation of adenovirus from 11 site. The presence of GVHD and multiple sites of adenovirus isolation have previously been identified as independent risk factors for adenovirus disease [9] . Possibly because of the high incidence of GVHD in both the invasive and noninvasive groups, the presence of GVHD was not a significant risk factor for infection in our study.
Not surprisingly, isolating adenovirus from 11 site correlated with increased risk for invasive disease. Twenty-five patients in our cohort (39%) had adenovirus isolated from 11 site. This is in contrast to the 19% of patients in a previous study [8] . It is not immediately clear why more patients in our review had multiple sites positive for adenovirus. Certainly, our policy of routine culturing could explain it. Patients who were less able to eradicate adenovirus had positive cultures from 11 site, a finding that may therefore simply indicate a later stage of the infection. We might think of adenovirus infection along a progressive continuum, asymptomatic at the start but yielding a single positive culture, and later characterized by multiorgan failure and positive cultures from multiple sites. Using this continuum as a model, one can hypothesize that there may exist a time, a "window of opportunity," before hematogenous dissemination during which disease can be detected and preemptive antiviral therapy instituted. With these concepts in mind, one can foresee potential benefit from strategies to detect virus before its dissemination. Having multiple sites positive for adenovirus may also be indicative of infections refractory to medical intervention, which highlights the need to develop effective therapeutic options.
Adenovirus infection was an important cause of death in our cohort. Confounding the cause of death in many cases was the fact that patients often had some degree of GVHD, venocclusive disease of the liver, interstitial pneumonitis, or other infectious processes at the time of death. In 26 patients, death was attributed to overwhelming infections, defined as infection with any pathogen with or without significant contribution from adenovirus. Eleven of those deaths could be definitively attributed to adenovirus alone, including 8 autopsy-confirmed cases. All but 2 patients with adenovirus cultured from 11 site had invasive infection and poorer survival. It cannot be concluded from our data that early intervention with antiviral therapy imparts a better survival. However, we postulate that early therapy in patients with more limited infections offers a better potential for response. To accomplish this, we need more effective ways of isolating adenovirus from tissues to identify patients earlier in their course, and more effective therapeutic options that are capable of eradicating the infection.
Autopsy can assist in the documentation of invasive adenovirus infections. In a study of 434 patients from whom adenovirus was recovered, autopsies were performed for 107 of the 286 patients who died. There was an 18% incidence of adenovirus in the autopsy population [11] . Of the 40 patients in our cohort who died, there were 18 autopsies (45%); adenovirus was recovered from 50% of these. The incidence of adenovirus recovered from an autopsy population following HSCT is typically higher than in survivors of transplantation. An increase in postmortem examinations in transplant patients could broaden our understanding of the role of adenovirus as a pathogen in immunocompromised patients.
The most common antiviral therapy used against adenovirus currently is ribavirin, which may be administered as an aerosol or iv formulation. Ribavirin is a relatively broad-spectrum antiviral agent that has been reported to have in vitro activity against various RNA and DNA viruses, including adenovirus [19, 20] . The pharmacokinetics and metabolism of iv ribavirin have been studied predominantly in normal volunteers [21] . Concentrations of ribavirin at the sites of infections have not been studied well. The in vivo efficacy of ribavirin has been demonstrated mostly through case reports [22] [23] [24] [25] [26] [27] . There is a need for randomized trials to study the efficacy of ribavirin in this setting. No factors associated with the infection are definite indicators of who will respond to therapy and who will not. However, on the basis of the data obtained in this review, there are clearly populations at greater risk of developing invasive adenovirus infections. Currently, it is our practice to initiate aerosolized and/or iv ribavirin therapy as soon as an adenovirus isolate is obtained from an HSCT patient. We believe that intervening with antiviral therapy as early as possible in the disease process may prevent more aggressive disseminated infections. We plan to test that hypothesis with an empirical therapy protocol initiating therapy with ribavirin for patients with a culture positive for virus.
